These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 38175973)
1. Updates on Systemic Therapy for Hepatocellular Carcinoma. Ntellas P; Chau I Am Soc Clin Oncol Educ Book; 2024 Jan; 44():e430028. PubMed ID: 38175973 [TBL] [Abstract][Full Text] [Related]
2. Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma: A Review. Cappuyns S; Corbett V; Yarchoan M; Finn RS; Llovet JM JAMA Oncol; 2024 Mar; 10(3):395-404. PubMed ID: 37535375 [TBL] [Abstract][Full Text] [Related]
3. Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. Han Y; Zhi WH; Xu F; Zhang CB; Huang XQ; Luo JF World J Gastroenterol; 2021 May; 27(19):2415-2433. PubMed ID: 34040331 [TBL] [Abstract][Full Text] [Related]
4. Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno-oncology: A network meta-analysis of randomized sorafenib-controlled trials. An J; Han S; Kim HI; Shim JH Hepatol Commun; 2022 Oct; 6(10):2886-2900. PubMed ID: 35785525 [TBL] [Abstract][Full Text] [Related]
5. Systemic therapies in hepatocellular carcinoma: A revolution? Fortuny M; Sanduzzi-Zamparelli M; Reig M United European Gastroenterol J; 2024 Mar; 12(2):252-260. PubMed ID: 38267015 [TBL] [Abstract][Full Text] [Related]
6. Combination immunotherapy for hepatocellular carcinoma. Rimassa L; Finn RS; Sangro B J Hepatol; 2023 Aug; 79(2):506-515. PubMed ID: 36933770 [TBL] [Abstract][Full Text] [Related]
7. Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients. Persano M; Rimini M; Tada T; Suda G; Shimose S; Kudo M; Cheon J; Finkelmeier F; Lim HY; Presa J; Masi G; Yoo C; Lonardi S; Tovoli F; Kumada T; Sakamoto N; Iwamoto H; Aoki T; Chon HJ; Himmelsbach V; Niizeki T; Montes M; Vivaldi C; Soldà C; Stefanini B; Hiraoka A; Sho T; Nishida N; Steup C; Iavarone M; Di Costanzo G; Marra F; Tamburini E; Cabibbo G; Foschi FG; Silletta M; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Campani C; Amadeo E; Rossari F; Burgio V; Cascinu S; Scartozzi M; Casadei-Gardini A Eur J Cancer; 2023 Aug; 189():112933. PubMed ID: 37385069 [TBL] [Abstract][Full Text] [Related]
8. Role of immunotherapy in the management of hepatocellular carcinoma: current standards and future directions. Weinmann A; Galle PR Curr Oncol; 2020 Nov; 27(Suppl 3):S152-S164. PubMed ID: 33343209 [TBL] [Abstract][Full Text] [Related]
9. Evolving therapeutic landscape of advanced hepatocellular carcinoma. Yang C; Zhang H; Zhang L; Zhu AX; Bernards R; Qin W; Wang C Nat Rev Gastroenterol Hepatol; 2023 Apr; 20(4):203-222. PubMed ID: 36369487 [TBL] [Abstract][Full Text] [Related]
10. Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease. Perera S; Kelly D; O'Kane GM Curr Oncol; 2020 Nov; 27(Suppl 3):S165-S172. PubMed ID: 33343210 [TBL] [Abstract][Full Text] [Related]
11. Emerging drugs for the treatment of hepatocellular carcinoma. Ayoub WS; Jones PD; Yang JD; Martin P Expert Opin Emerg Drugs; 2022 Jun; 27(2):141-149. PubMed ID: 35642526 [TBL] [Abstract][Full Text] [Related]
12. The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence. Cerreto M; Cardone F; Cerrito L; Stella L; Santopaolo F; Pallozzi M; Gasbarrini A; Ponziani FR Curr Oncol; 2023 Sep; 30(10):8774-8792. PubMed ID: 37887533 [TBL] [Abstract][Full Text] [Related]
15. AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma. Su GL; Altayar O; O'Shea R; Shah R; Estfan B; Wenzell C; Sultan S; Falck-Ytter Y Gastroenterology; 2022 Mar; 162(3):920-934. PubMed ID: 35210014 [TBL] [Abstract][Full Text] [Related]
16. Hepatocellular Carcinoma: Advances in Systemic Therapy. Selene II; Ozen M; Patel RA Semin Intervent Radiol; 2024 Feb; 41(1):56-62. PubMed ID: 38495258 [TBL] [Abstract][Full Text] [Related]
17. Advances in novel systemic therapies for advanced hepatocellular carcinoma. Carloni R; Rizzo A; Cusmai A; Palloni A; Federico AD; Marco MD; Massafra R; Fanizzi A; Palmiotti G; Brandi G Future Med Chem; 2022 Oct; 14(20):1455-1470. PubMed ID: 35997677 [TBL] [Abstract][Full Text] [Related]
19. Hepatocellular carcinoma, novel therapies on the horizon. El Dika I; Makki I; Abou-Alfa GK Chin Clin Oncol; 2021 Feb; 10(1):12. PubMed ID: 32527116 [TBL] [Abstract][Full Text] [Related]
20. Atezolizumab in Combination with Bevacizumab for the Management of Patients with Hepatocellular Carcinoma in the First-Line Setting: Systematic Literature Review and Meta-Analysis. Vogel A; Finn RS; Blanchet Zumofen MH; Heuser C; Alvarez JS; Leibfried M; Mitchell CR; Batson S; Redhead G; Gaillard VE; Kudo M Liver Cancer; 2023 Dec; 12(6):510-520. PubMed ID: 38058419 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]